Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins
Dana S. Neel(University of California, San Francisco), Trever G. Bivona(University of California, San Francisco), Collin M. Blakely(City College of San Francisco), Golzar Hemmati(University of California, San Francisco), Caroline E. McCoach(Memorial Sloan Kettering Cancer Center), Robert C. Doebele(Aurora University), Rafael Rosell(Hospital Universitario Dexeus), Manasi K. Mayekar(University of California, San Francisco), Julia Rotow(University of California, San Francisco), Victor Olivas(University of California, San Francisco), David V. Allegakoen(University of California, San Francisco), Jonathan W. Riess(University of California Davis Medical Center), Niki Karachaliou(Institut Català d'Oncologia), Anh T. Le(University of Colorado Anschutz Medical Campus), Nilanjana Chatterjee(University of California, San Francisco), Robert J. Nichols(Revolution Medicines (United States))
Cited by 98
Related Papers
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k